ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Missing protein explains link between obesity, diabetes

Fish oil use associated with brain volume preservation

The Brain Boosting and Fatigue Fighting B-12

Genetic basis for distinct type of autism uncovered

Unsuspected aspect of immune regulation revealed: Role of B cells

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

Explaining 'Healthy' Obesity

Sinus Congestion and Sinusitis, Healing Naturally

Omega 3 Fatty Acids Lessen Severity of Osteoarthritis in Mice

In the gut, immunity is a two-way street

 
Print Page
Email Article

Omega-3 ratio for positive depression effect is 60% or more EPA

  [ 15 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 25, 2011


Article:
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression – Source: Journal of Clinical Psychiatry, Sep 6, 2011

By M Elizabeth Sublette, MD, PhD, et al.

[Note: The full text pdf of this article can be found at http://www.tritolonen.fi/files/pdf/Sublette_2011.pdf. It includes a discussion of various hypotheses regarding why these EPA-DHA ratios and relative daily amounts provide therapeutic benefit for primary depression. DHA & EPA are found mainly in fish oil. ]

Abstract:
Objective: Randomized trials of omega-3 polyunsaturated fatty acid (PUFA) treatment for depression have differed in outcome. Recent meta-analyses ascribe discrepancies to differential effects of eicosapentaenoic acid (EPA) versus docosahexaenoic acid (DHA) and to diagnostic heterogeneity.

This meta-analysis tests the hypothesis that EPA is the effective component in PUFA treatment of major depressive episodes.

Data Sources: PubMed/MeSH was searched for studies published in English from 1960 through June 2010 using the terms fish oils (MeSH) AND (depressive disorder [MeSH] OR bipolar depression) AND randomized controlled trial (publication type). The search was supplemented by manual bibliography review and examination of relevant review articles.

Study Selection: The search yielded 15 trials involving 916 participants. Studies were included if they had a prospective, randomized, double-blinded, placebo-controlled study design; if depressive episode was the primary complaint (with or without comorbid medical conditions); if omega-3 PUFA supplements were administered; and if appropriate outcome measures were used to assess depressed mood.

Data Extraction: Extracted data included study design, sample sizes, doses and percentages of EPA and DHA, mean ages, baseline and endpoint depression ratings and standard deviations for PUFA and placebo groups, and P values.

The clinical outcome of interest was the standardized mean difference in the change from baseline to endpoint scores on a depression rating scale in subjects taking PUFA supplements versus subjects taking placebo.

Data Synthesis: In a mixed-effect model, percentage of EPA in the supplements was the fixed-effect predictor, dichotomized into 2 groups: EPA less than 60% or EPA 60% or more of the total EPA + DHA. Secondary analyses explored the relevance of treatment duration, age, and EPA dose.

Results:

• Supplements with 60% or more EPA [of total EPA + DHA] showed benefit on standardized mean depression scores (effect size = 0.532; 95% CI, 0.277–0.733; t = 4.195; P < .001) versus supplements with less than 60% EPA (effect size = -0.026; 95% CI, -0.200 to 0.148; t = -0.316; P = .756), with negligible contribution of random effects or heteroscedasticity and with no effects of treatment duration or age.

• Supplements with less than 60% EPA were ineffective.

Exploratory analyses supported a nonlinear model, with improvement determined by the dose of EPA in excess of DHA, within the range of 200 to 2,200 mg/d of EPA.

Conclusions:

• Supplements containing 60% or more EPA of total EPA + DHA, in a dose range of 200 to 2,200 mg/d of EPA in excess of DHA, were effective against primary depression.

• Translational studies are needed to determine the mechanisms of EPA’s therapeutic benefit.

Source: Journal of Clinical Psychiatry, Sep 6, 2011. PMID:21939614, by Sublette ME, Ellis SP, Geant AL, Mann JJ. New York State Psychiatric Institute, New York, NY, USA. [Email: es2316@columbia.edu]





Discuss This Article Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Broad Spectrum Protection Against Brain Aging Broad Spectrum Protection Against Brain Aging
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing